Viking Therapeutics Adds Commercialization Expert Dorothy Gemmell to Board
Event summary
- Viking Therapeutics appointed Dorothy Gemmell to its Board of Directors on July 23, 2026.
- Gemmell brings over 25 years of leadership experience in healthcare, digital health, and commercialization.
- She previously served as president or chief commercial officer at GoodRx, Capsule, and Havas Life.
- Viking's lead program, VK2735, is currently in Phase 3 clinical studies for obesity.
The big picture
Viking Therapeutics is bolstering its commercialization capabilities ahead of potential VK2735 launch. The appointment comes as the company navigates a competitive landscape for obesity treatments, with Gemmell's background in scaling healthcare organizations positioning Viking to strengthen its market entry strategy.
What we're watching
- Commercialization Strategy
- How Gemmell's expertise will shape Viking's go-to-market approach for VK2735.
- Pipeline Progress
- The pace at which Viking advances its obesity and metabolic disease pipeline.
- Market Positioning
- Whether Viking can differentiate itself in the competitive obesity treatment space.
Related topics